Thigpen Tate
Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Clin Obstet Gynecol. 2012 Mar;55(1):114-30. doi: 10.1097/GRF.0b013e31824b9bc5.
Evidence supports the current paradigm for the management of patients with recurrent or persistent ovarian carcinoma. The paradigm requires that patients be classified as platinum-sensitive or platinum-resistant. Patients who achieve a complete response with platinum-based therapy and experience at least 6 months free from recurrence should be categorized as having chemosensitive disease and should be retreated with carboplatin-based doublets. Patients who progress while receiving treatment, whose best response is stable disease, or who experience a complete response of <6 months duration should be categorized as having chemoresistant disease and should be treated with a nonplatinum single agent.
有证据支持目前复发性或持续性卵巢癌患者的管理模式。该模式要求将患者分为铂敏感型或铂耐药型。接受铂类疗法后达到完全缓解且至少6个月无复发的患者应归类为化疗敏感疾病，应接受以卡铂为基础的双联化疗。在接受治疗期间病情进展、最佳反应为病情稳定或完全缓解持续时间<6个月的患者应归类为化疗耐药疾病，应接受非铂类单药治疗。
